What does Oxytocin do? Benefits and evidence
A hormone used during childbirth; nasal social and weight-loss benefits remain unproven.
Also called: Pitocin, Syntocinon, OT, OXT, TTA-121.
Neuropeptides · Oxytocin-receptor agonist and uterotonic hormone · Evidence: Approved drug.
Oxytocin is a hormone used in hospitals to stimulate labour and control bleeding after birth. Larger nasal-spray trials found no benefit over placebo for social functioning in children with autism or weight loss in adults with obesity. Injection and nasal doses are not interchangeable. Too much can cause dangerous contractions, heart effects or low sodium.
- Pitocin is approved as a hospital injection to start or help labour and to control bleeding after birth. (Drug label)
- In a study of 29 couples, some measures of orgasm improved with nasal oxytocin, though desire and arousal did not change. (Studied in a trial)
- In a trial in people with frontotemporal dementia, on-and-off nasal doses slightly reduced apathy. (Studied in a trial)
- One user reported less social anxiety and another less dislike of being touched; others noticed little effect. (Reported by users)
Uses in the sources
- Approved hospital injections start or support medically indicated labour, aid selected abortion care and control bleeding after birth. (Drug label) (source)
- Nasal oxytocin has been studied for autism. Large trials and the 2026 pooled review found no reliable overall social benefit. (Studied in a trial) (source)
- Acute studies sometimes reduce one meal. The larger 8-week trial found +0.20 kg with oxytocin versus +0.26 kg with placebo. (Studied in a trial) (source)
- A 29-couple study found no change in drive, arousal, erection or lubrication. Some subjective orgasm measures improved. (Studied in a trial) (source)
- Studied for feeding in Prader-Willi syndrome and apathy in frontotemporal dementia. Benefits were limited to selected outcomes. (Studied in a trial) (source)
- People report nasal sprays and injections for bonding, mood or sleep. Reports include no effect, flushing and severe nausea or dizziness. (Reported by users) (source)
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- PITOCIN- oxytocin injection, Par Health USA, LLC · DailyMed · 2026
- Search results summary, Health Canada · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Understanding the Risks of Compounded Drugs, FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Oxytocin 10 IU/ml Solution for infusion - Summary of Product Characteristics (SmPC), electronic medicines compendium · 2025
- Postpartum interventions to prevent postpartum haemorrhage, World Health Organization · 2025
- WHO recommendations on maternal and newborn care for a positive postnatal experience, World Health Organization · 2022
- Syntometrine, Phebra Pty Ltd · Australian Commission on Safety and Quality in Health Care · 2019
- PSUSA/00002263/201706 - periodic safety update report single assessment, EMA · 2018
- Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Guidance for Industry, FDA · 2016
- Oxytocin (Aspen), Healthdirect Australia
- SYNTOCINON oxytocin 10 IU/1 mL injection ampoule (13383), Therapeutic Goods Administration
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.